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The receptor for advanced glycation endproducts (RAGE) can engage a diverse class
of ligands and contribute to the immune and inflammatory response to infection and
injury. It is known to be a pathogenic receptor in many inflammatory diseases, including
ischemia/reperfusion (IR) injuries in several tissues; however, its role has not been
investigated in IR injuries of the intestine to date. Mesenteric (or intestinal) IR leads to
recruitment of inflammatory cells into intestinal interstitial spaces, which markedly disrupts
intestinal mucosa. IR-induced mucosal injury is accompanied by the development of a
local and systemic inflammatory response and remote organ injury, and results in high
mortality in the clinic. We hypothesized that elimination of RAGE signaling using RAGE / 
mice would result in decreased local and remote organ injury and reduced inflammation
in a mesenteric IR model, and thus be a target for therapeutic intervention. We found that
RAGE ligands including HMGB-1 and C3awere elevated after mesenteric IR indicating the
potential for enhanced RAGE activation in this model. However despite this, wild-type and
RAGE /  mice both displayed similar degrees of mesenteric injury, neutrophil infiltration,
intestinal edema, cytokine generation, neutrophil mobilization, and remote organ injury
after mesenteric IR. We, therefore, conclude that despite its role in other organ IR injuries,
and the robust production of RAGE ligands after intestinal ischemia, RAGE itself does not
directly influence tissue injury and the inflammatory response in mesenteric IR.
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INTRODUCTION
The gastrointestinal tract takes up a significant portion of individual circulating blood, and a
decrease in blood supply to the intestine even for a short period due to systemic hypotension,
major cardiovascular surgery or trauma, can lead to intestinal ischemia (1). Delayed presentation
of intestinal ischemia renders the in-hospital mortality rate still above 60% (2). Clinicians also
encounter the problems associatedwith the salvage of ischemic gut, where reperfusion leads to a local
and systemic inflammatory response that exacerbates tissue destruction and other complications,
termed ischemia/reperfusion (IR) injuries (3).
The receptor for advance glycation endproducts (RAGE) is a transmembrane innate immune
receptor that upon ligation can induce a variety of inflammatory responses and oxidative stress (4, 5).
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RAGE is capable of interacting with several ligands, including its
namesake glycoprotein advanced glycation endproducts (AGE),
high-mobility group protein box 1 (HMGB-1), S100 proteins, and
complement fragment 3a (C3a) (6, 7). Given the large number of
RAGE ligands associated with the inflammatory response, activa-
tion of this receptor has a critical impact on facilitating chronic
diseases via chronic inflammation, for example diabetic condi-
tions andAlzheimer’s disease (8, 9). It is also strongly implicated in
the pathogenesis of IR injuries, with several studies demonstrating
genetic deficiency or inhibition of RAGE to be protective in IR
injuries to the heart, liver, lung, and brain (10–13). To date,
however, no studies have addressed whether RAGE is pathogenic
during the development of intestinal IR injury.
Intestinal IR injuries in the mouse lead to a variety of patho-
logical sequela including mobilization and recruitment of neu-
trophils, oxidative damage, edema, production of inflammatory
cytokines, and systemic inflammation leading to remote organ
injury (14). Given that RAGE activation can contribute to many
of these same pathways and inhibition of RAGE is protective in IR
injuries of other organs, this suggests that RAGE blockade could
be a therapeutic target for treating intestinal IR injuries. In this
study, we therefore aimed to determine the pathogenic role of
RAGE in intestinal IR injury. We first measured RAGE ligand
levels after mesenteric IR and then measured mucosal damage
in RAGE deficient (RAGE / ) mice. In addition, inflammatory
cells, inflammatory mediators, and injury markers were also mea-
sured. Interestingly, we found that despite an upregulation of
RAGE ligands following mesenteric IR, deficiency of RAGE did
not impact on the disease pathology, suggesting other signaling
pathways predominate in this model.
MATERIALS AND METHODS
Animals
Male C57BL/6 wild-type (WT) mice and RAGE signaling-
deficient mice (RAGE / ) on a C57BL/6J genetic background
were maintained at the University of Queensland’s Biological
Resources Animal Facilities under specific pathogen free con-
ditions. Male mice aged 10–12weeks weighing 20–25 g were
selected for all experiments. Homozygous RAGE /  mice have
the extracellular domain of RAGE (exons 2–7) removed and thus
express a non-functional RAGE protein (15, 16). The experimen-
tal protocols were approved by the University of Queensland’s
Animal Ethics Committee.
Intestinal Ischemia Reperfusion Injury
Model
Mice were anesthetized by a ventilated system containing 4%
of isoflurane with oxygen supply (2 L/min) during the surgi-
cal operation. To induce mesenteric IR, the superior mesenteric
artery (SMA) was exposed and occluded with a loop ligature
for 30min to induce non-traumatic intestinal ischemia as previ-
ously described (17, 18). The ligature was then removed to allow
intestinal tissue reperfusion for 150min, which results in moder-
ate–severe intestinal damage (18). Both WT and RAGE /  mice
underwent IR surgery. To establish a baseline, sham-operated
WT mice underwent the same surgical procedures, but the SMA
was not occluded. Following the reperfusion phase, mice were
then euthanatized, and pieces of intestinal tissue from the dis-
tal jejunum/early ileum and whole blood [collected in 1mg/mL
EDTA and 0.1mg/mL nafamostat mesylate (19)] were obtained
for other analyses described below.
Histology and Tissue Injury Evaluation
Tissues were fixed in 4% paraformaldehyde (Sigma-Aldrich, USA)
for a minimum of 72 h and embedded in paraffin. Tissue sections
(6μm) were stained with hematoxylin and eosin (H&E) by fol-
lowing a standard H&E staining protocol. Tissue injury score was
determined in a blinded fashion using a graded scale adapted from
Chiu et al. (20).
Wet/Dry Weight
A portion of the intestine (5–10 cm) was weighed to obtain wet
weight (g). The tissue was allowed to dry for 48 h at 80°C and
weighed for dry weight. Wet/dry weight ratio, as a measure
of edema, was calculated by the formula: wet weight (g)/dry
weight (g).
Myeloperoxidase Level
Neutrophil accumulation and activation in the tissue was quan-
titated by the level of myeloperoxidase enzyme in the tis-
sue. A portion of intestine was homogenized and sonicated in
phosphate buffered saline (PBS; pH 6.0) containing 1% pro-
tease inhibitor cocktail (Merck-Millipore, USA) and 0.5% Hta-Br
(Sigma-Aldrich, USA). The homogenate was incubated with the
substrate containing 2.85mg/mL O-dianisidine and 2.3% hydro-
gen peroxide in deionized water. The absorbance of the sample
was then measured spectrophotometrically at 460 nm at 15min
and normalized to the total protein level of the homogenate mea-
sured by BCA protein Assay (Thermo Fisher Scientific, Australia).
Intestinal Neutrophil Staining (Leder’s
Stain)
Neutrophils in the intestine were stained using a naphthol AS-D
chloroacetate esterase cytochemical staining kit (Sigma-Aldrich,
USA), which identifies specific leukocyte esterases predominantly
expressed in granulocytic neutrophils. Harvested tissues were
fixed in 4% paraformaldehyde, embedded in paraffin and, micro-
tome sectioned and then stained with naphthol esterase solution,
according to the manufacturer’s protocol. Cells with bright-red
granulations in themucosa were counted in a blindedmethod and
expressed as the number of neutrophils per villus.
Leukocyte and Neutrophil Count
EDTA blood (1mg/mL) was collected from the inferior vena-
cava and centrifuged. White blood cells were isolated by lysing
erythrocytes with red blood cell lysis solution (0.85% ammonium
chloride in PBS) followed by hypotonic shock (21). Total leukocyte
numbers were determined by using an up-right light microscopy
and a hematocytometer. The neutrophil population (%) was iden-
tified and counted in triplicate blood smears stained by Diff-Quik
staining kit (ThermoFisher Scientific, Australia). Circulating neu-
trophil countswere calculated bymultiplying total white blood cell
count (cells per millilitre) to neutrophil population (%).
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Alanine Transaminase and Alkaline
Phosphatase
Liver injury was quantified by measuring alanine transaminase
(ALT) and alkaline phosphatase (ALP) levels in the plasma as
previously described (22) and according to the manufacturer’s
instructions (ALT and ALP reagents; Thermo Fisher Scientific,
Australia).
Inflammatory Protein Levels
Plasma cytokines, HMGB-1, and IL-6 and complement factor C3a
levels were measured by enzyme-linked immunosorbent (ELISA)
kits (Chondrex, USA; BD Biosciences, Australia), according to
their manufacturers’ instructions. The concentrations of these
proteins for the samples were calculated by using a linear regres-
sion analysis of their correspondent standard curves.
Statistics
All experimental results are expressed as mean SEM. Data anal-
ysis was performed using GraphPad Prism 6.0 software (Graph-
Pad software, Inc., USA). Statistical comparisons weremade using
a one-way ANOVA with Dunnett’s post-test, or t-test (two-tailed
distribution).
RESULTS
Mesenteric IR Induces Release of Ligands
for RAGE
There are several molecules that are reported to interact with
RAGE and that include the damage-associated molecular pattern
(DAMP) molecule, secreted HMGB-1, and the complement acti-
vation fragment C3a, both of which are generated following tissue
injury (6, 7). To assess whether our mouse model of IR injury
generated these RAGE ligands, HMGB-1 and C3a systemic blood
concentrations were measured by using standard ELISAs. The
plasma concentration of HMGB-1 was dramatically increased by
approximately 12-fold following IR, compared to sham-operated
IR mice (Figure 1A). We also found a twofold increase in C3a
plasma concentrations after IR compared to sham-operated mice
(Figure 1B). These data show that the intestinal IR setting induced
elevations of RAGE ligands in the circulation, and thus indicates
the potential for enhanced RAGE activation after mesenteric IR.
Elimination of RAGE Does Not Reduce
Mucosal Injury Following Mesenteric IR
Mesenteric IR induces a marked damage to intestinal mucosa. In
our study, haemotoxylin and eosin staining demonstrated mesen-
teric IR-induced mucosal damage which included villus epithelial
lifting/loss and lamina propria swelling (Figure 2A), compared
sham-operation (Figure 2B). This mucosal damage caused by IR
was not mitigated in RAGE deficient (RAGE / ) mice undergo-
ing IR (Figure 2C). Tissue damage was semi-quantitated by scor-
ing tissue from individual mice in a blinded manner, demonstrat-
ing elimination of RAGE had no significant impact on intestinal
injury scores after IR (Figure 2D).
Next, tissue edema was measured as an indicator of vascu-
lar leakage of a common pathological event following mucosal
damage. Mesenteric IR induced an increase in intestinal wet/dry
weight ratios, however, elimination of RAGE had no impact on
the water content in the intestine after IR (Figure 2E).
Neutrophils are a key player of the villi destruction in intestinal
IR injury (14). We examined neutrophil accumulation by staining
intestinal sections for neutrophils and measuring myeloperox-
idase levels in the IR-injured intestines (18). As expected, IR
induced a marked increase in neutrophil accumulation in the
injured intestine and increased myeloperoxidase levels; however,
elimination of RAGE did not show any significant alteration in
neutrophil accumulation after IR (Figures 2F,G).
Elimination of RAGE Does Not Impact
White Blood Cell and Neutrophil
Mobilization Following Mesenteric IR
We have previously shown that intestinal reperfusion is strongly
accompanied by a rapid mobilization of leukocytes (predomi-
nantly neutrophils) from bone marrow reservoirs into the circu-
lation (18). Furthermore, the degree of neutrophil mobilization is
correlated to the degree of neutrophil infiltration into the reper-
fused intestine and subsequent intestinal injury, and thus a key
disease parameter of the potential for IR injury (18). As in our
prior studies, mesenteric IR induced increases in both circulating
white blood cells (Figure 3A), which were chiefly neutrophils
(Figure 3B). However, again as for mucosal injury markers, the
numbers of mobilized leukocytes or neutrophils were not affected
by eliminating RAGE signaling (Figures 3A,B).
FIGURE 1 | Intestinal ischemia reperfusion (IR) injury induces systemic blood elevation of RAGE ligands. Wild-type (WT) mice were subjected to 30min
mesenteric artery occlusion, followed by 150min of reperfusion to induce intestinal IR injury. Alternatively, sham-operated mice underwent the same procedure,
except the mesenteric artery was not occluded (SHAM). The plasma levels of (A) HMGB1 and (B) C3a were measured using standard ELISA kits at the end of the
reperfusion period. Data are presented as meanSEM, n= 4 (WT-SHAM) n= 8 (WT-IR) where *p<0.05, **p<0.01 compared with WT-SHAM.
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FIGURE 2 | Elimination of RAGE signaling does not impact mucosal damage and neutrophil accumulation following mesenteric IR. Mice were
subjected to 30min mesenteric artery occlusion, followed by 150min reperfusion. (A–C) Representative H&E staining of cross-sections of ileum from
(A) sham-operated wild-type mice (WT-SHAM), (B) mesenteric IR wild-type mice (WT-IR), and (C) mesenteric IR RAGE /  mice (RAGE /  IR) groups. Scale
bar=50μm. The mucosal injury was semi-quantitated as expressed as histopathological index (D) demonstrating no significant effect on IR injury following RAGE
elimination. Increases in intestinal edema, as measured by wet/dry weight ratios (E), were also not impacted by RAGE signaling elimination. Similar results were seen
following quantification of myeolperoxidase levels in intestinal homogensates, normalized by total protein levels (F), and esterase stained (Leder’s) neutrophil counts in
the entire cross-section of intestine and normalized to number of villi (G). Data are presented as meanSEM, n= 5 (WT-SHAM); n= 13 (WT-IR); n= 15 (RAGE / 
IR) where *p<0.05, ***p<0.001, and ns= not-significant (p>0.05).
Elimination of RAGE Does Not Reduce
Remote Organ (Liver) Injury and Systemic
Inflammation Following Mesenteric IR
Systemic inflammation and remote organ injury are often com-
plications in intestinal IR injury (23, 24), which can lead to
significant morbidity and mortality. We, therefore, finally exam-
ined liver injury markers, alanine aminotransferase (ALT), and
ALP and pro-inflammatory mediators, including HMGB-1 and
interleukin-6 (IL-6) in the peripheral blood after mesenteric IR.
We found IR-induced significant elevations in plasma ALT and
ALP, however as in the other parameters, elimination of RAGEdid
not significantly alter these elevations (Figures 4A,B). Moreover,
HMGB-1 and IL-6 concentrations in the plasma were signifi-
cantly increased followingmesenteric IR. However, these two pro-
inflammatory proteins were not altered in RAGE / mice after IR
(Figures 4C,D).
DISCUSSION
In this study, we aimed to determine the role of RAGE in
the progression of mesenteric IR-induced tissue injury and
inflammation. Our hypothesis was that RAGE would contribute
to the pathology associated with reperfusion injury, in line with
its known pro-inflammatory role, and its documented role in
Frontiers in Immunology | www.frontiersin.org December 2015 | Volume 6 | Article 6144
Wu et al. RAGE in Gut IR Injury
FIGURE 3 | Elimination of RAGE does not affect total white blood cell and blood neutrophil counts following intestinal IR. Mice were subjected to 30min
mesenteric artery occlusion, followed by 150min reperfusion. The numbers of (A) white blood cells (WBC) and (B) neutrophils, in the peripheral blood collected after
150min reperfusion, demonstrating that RAGE does not influence IR-induced leukocyte or neutrophil mobilization. Data are presented as meanSEM, n= 5
(WT-SHAM); n= 13 (WT-IR); n= 15 (RAGE /  IR) where *p<0.05, **p<0.01, and ns= not-significant (p>0.05).
FIGURE 4 | Elimination of RAGE does not influence remote organ (liver) injury and systemic inflammation following intestinal IR. Mice were subjected to
30min mesenteric artery occlusion, followed by 150min reperfusion. Peripheral blood samples were collected from WT-SHAM, WT-IR, and RAGE /  IR groups for
enzyme activity and pro-inflammatory markers. (A,B) Activities of liver enzymes ALT (A) and ALP (B) measured as markers of liver injury. (C,D) Levels of
pro-inflammatory mediators HMGB-1 (C) and IL-6 (D). Data are presented as meanSEM, n= 5 (WT-SHAM); n= 13 (WT-IR); n= 15 (RAGE /  IR) where
*p<0.05, **p<0.01, and ns= not-significant (p>0.05).
propagating IR injuries in other organs (10–13). We first iden-
tified that ligands for RAGE, HMGB-1 and C3a, in the circu-
lation were elevated after 30min ischemia followed by 150min
reperfusion in the intestine, indicating that enhanced RAGE-
signaling was feasibly increased after mesenteric IR. We then
used RAGE /  mice to determine the effect of RAGE absence
in intestinal IR injury. Interestingly, we found that all local and
remote injury parameters measured including mucosal injury,
intestinal edema and neutrophil infiltration, neutrophil mobiliza-
tion and pro-inflammatory cytokine production, and liver injury
markers were not altered by a lack of RAGE-signaling. Overall,
these results clearly demonstrate that RAGE is not a critical
receptor in the pathogenesis of intestinal IR-induced local injury,
systemic inflammation and remote organ damage.
Mesenteric IR accounts for a high mortality rate in the hos-
pital setting, and there is no adequate therapy. A severe pro-
inflammatory response is seen upon reperfusion of the ischemic
intestine, and leads to tissue destruction and remote organ failure.
Thus, numerous therapies have been proposed to treat intestinal
IR injury, particularly those targeting the innate immune system
responding to alarmins produced by the ischemic tissue. RAGE
is a key innate immune receptor that can interact with multiple
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and diverse ligands, many of which are produced following tissue
ischemia, and has been reported to participate in a number of
acute and chronic inflammatory diseases through downstream
signaling mechanisms of immune and inflammatory responses
(25–27). Indeed, in the setting of IR, several studies have described
the pathogenic contribution of RAGE in injuries of the liver, lung,
heart, and brain (10–13, 28).
One of the key ligands for RAGE is the secreted alarmin/DAMP
HMGB-1, which has been clearly documented to mediate pro-
inflammatory effects when activating this receptor (7, 29), and is
suggested to be a key therapeutic target to reduce tissue injury
(11, 12, 30). In our mesenteric IR model, we demonstrated that
the levels of HMGB-1 were significantly upregulated following IR.
We also showed that another ligand for RAGE, the innate immune
complement factor C3a (31), was similarly elevated, indicating the
potential for multiple ligands interacting with RAGE, which is
expressed onmany pro-inflammatory cells involved in IR, includ-
ing within the intestine (32). Despite this potential for enhanced
RAGE activation and pro-inflammatory induction, eliminating
RAGE signaling in RAGE /  mice did not protect local mucosal
injury, neutrophil influx and vascular leakage, as well as remote
organ liver damage caused by mesenteric IR. Interestingly, Dess-
ing et al. (33) similarly showed that RAGE deficiency does not
affect renal injury and function after renal IR, despite RAGE
ligands HMGB-1 and S100B being expressed (33). They suggest
that RAGE is likely not the primary effector of HMGB-1 in renal
IR injury, but rather other innate immune receptors such as the
toll-like receptors (TLRs) could be predominating in the pro-
inflammatory response. Our study agrees with these findings, and
indeed TLRs are known to playmajor roles in intestinal IR injuries
(34).
RAGE–ligand interaction also leads to activation of pro-
inflammatory transcription factor nuclear factor kappa B and its
downstream target genes, inducing release of pro-inflammatory
cytokines such as TNF, IL-1, IL-6, and IL-8 in different cell
types (35, 36). We have previously shown IL-6 to be a principal
cytokine elevated in the circulation following mesenteric IR (18,
37). In this study, we found, however, that circulating IL-6 (or
HMGB1) was not reduced by a lack of RAGE signaling in the IR
pathological setting, suggesting a minor role of RAGE in medi-
ating this cytokine release following mucosal injury due to IR.
Furthermore, our results also demonstrate that RAGE does not
contribute to the intestinal infiltration of neutrophils following
mesenteric IR injury. In accordance with these data, leukocyte
mobilization following intestinal IRwas not altered by the absence
of RAGE signaling. Together, this may contribute to the lack of
tissue protection in RAGE /  mice, as neutrophils are known to
be key mediators of IR-induced injury (14).
In conclusion, we highlight that deletion of RAGE signaling
is not protective against IR-induced mucosal and remote organ
injury and systemic inflammation, suggesting that RAGE does
not play a role in the pathogenesis of intestinal IR injury in the
mouse. Due to the multi-ligand nature of RAGE, in the absence of
RAGE, these ligands may favor other pro-inflammatory receptors
(such as toll-like receptors), and hence the protective effect of
RAGE deletion may be effectively compensated for. Our study
thus suggests that blockade of RAGE is not a credible therapeutic
target for mesenteric IR injuries.
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